“Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b 4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s420. Accessed July 3, 2025. https://skin.dermsquared.com/skin/article/view/3088.